Table 2.
Ongoing clinical trials in Osimertinib-resistant EGFR-mutated NSCLC.
| Clinical Trial Number | Phase | Treatment Arms | Primary Endpoint | Link to the Clinical Trial |
|---|---|---|---|---|
| NCT03515837 | III | Pembrolizumab + pemetrexed + chemo vs. placebo + pemetrexed + chemo |
PFS, OS | https://clinicaltrials.gov/ct2/show/NCT03515837 (accessed on 28 January 2022) |
| NCT03778229 | II | Osimertinib + savolitinib | ORR | https://www.clinicaltrials.gov/ct2/show/NCT03778229 (accessed on 28 January 2022) |
| NCT03944772 | II | Osimertinib + savolitinib vs. osimertinib + gefitinib vs. osimertinib + necitumumab vs. durvalumab + carboplatin + pemetrexed |
ORR | https://www.clinicaltrials.gov/ct2/show/NCT03944772 (accessed on 28 January 2022) |
| NCT03940703 | II | Tepotinib + osimertinib | Safety, ORR | https://clinicaltrials.gov/ct2/show/NCT03940703 (accessed on 28 January 2022) |
| NCT04136535 | II | Pemetrexed and carboplatin with or without anlotinib | PFS | https://www.clinicaltrials.gov/ct2/show/NCT4136535 (accessed on 28 January 2022) |
| NCT03532698 | II | Osimertinib + aspirin | ORR | https://www.clinicaltrials.gov/ct2/show/NCT03532698 (accessed on 28 January 2022) |
| NCT04316351 | II | Toripalimab + pemetrexed + anlotinib | ORR | https://www.clinicaltrials.gov/ct2/show/NCT04316351 (accessed on 28 January 2022) |
| NCT03784599 | I/II | Trastuzumab emtansine and osimertinib | Safety, ORR | https://www.clinicaltrials.gov/ct2/show/NCT03784599 (accessed on 28 January 2022) |
| NCT03891615 | I | Osimertinib + Niraparib | MTD | https://www.clinicaltrials.gov/ct2/show/NCT03891615 (accessed on 28 January 2022) |
| NCT03516214 | I | Nazartinib and trametinib | MTD; RP2D | https://www.clinicaltrials.gov/ct2/show/NCT03516214 (accessed on 28 January 2022) |
EGFR: Epidermal Growth Factor Receptor. NSCLC: Non-Small-Cell Lung Cancer. MDT: maximum tolerated dose. OS: Overall Survival. PFS: Progression-Free Survival. RP2D: recommended phase II dose. ORR: Objective response rate.